[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: [68Ga]Ga-NeoB
DRUG: [177Lu]Lu-NeoB
DRUG: Ribociclib
DRUG: Fulvestrant
OTHER: Goserelin

Sponsor

Novartis Pharmaceuticals